Targeted failure of the week. Post No 104. CVac

Prima BioMed Ltd. (ASX:PRR; NASDAQ:PBMD) was off $0.74 (31%) to $1.61 on NASDAQ on Wednesday after reporting no observed difference between the CVac and observation arms in estimated median progression-free survival (PFS), the primary efficacy endpoint, in the Phase II CAN-003 trial to treat ovarian cancer in patients in first or second remission.

 

CVac is an ex vivo cancer vaccine using a patient's own dendritic cells primed with a tumor antigen mucin 1 (MUC1; CD227) and a mannan-fusion protein (M-FP).